Dr. Lal PathLabs Increases Stake in Centrapath Labs to 100%

Transaction Price: INR 1,608.35 per share | Final stake acquired: 30%

Reader Takeaway: Consolidation simplifies management and control of the diagnostic unit without impacting equity through new share issuance.

What just happened

Dr. Lal PathLabs Ltd, through its wholly-owned subsidiary PathLabs Unifiers Private Limited (PUPL), has acquired the remaining 30% equity stake in Centrapath Labs Private Limited (CPL). The deal was executed via a cash consideration at a price of INR 1,608.352 per share. Following this transaction, CPL is now a wholly-owned subsidiary of PUPL. The company has confirmed this is not a related party transaction.

Why this matters

The acquisition completes the total integration of Centrapath Labs into the Dr. Lal PathLabs ecosystem. By moving to a 100% ownership model, the parent company gains full control over the diagnostic unit’s operations and strategic decision-making in the Madhya Pradesh region. For investors, the cash-based nature of the deal is a positive sign as it avoids equity dilution for existing shareholders.

Context metrics

Centrapath Labs, incorporated in 2019 in Indore, has reported turnover figures of INR 20.8 crore in FY 2024, INR 23.7 crore in FY 2025, and INR 20.5 crore in FY 2026. This consolidation reflects a move to centralize governance within the group's subsidiary network.